ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2009
Alogliptin: a new addition to the class of DPP-4 inhibitors.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Alogliptin as an initial therapy in patients with newly diagnosed, drug naïve type 2 diabetes: a randomized, control trial.Endocrine · 2012Trial
- Dipeptidyl Peptidase 4 Inhibitors: Novel Therapeutic Agents in the Management of Type II Diabetes Mellitus.Pharmacoepidemiology and drug safety · 2025Review
- Article
- Discovery of imeglimin-inspired novel 1,3,5-triazine derivatives as antidiabetic agents in streptozotocin-induced diabetes in Wistar ratsRSC medicinal chemistry · 2023Article
- In Silico Development of Combinatorial Therapeutic Approaches Targeting Key Signaling Pathways in Metabolic Syndrome.Pharmaceutical research · 2022Article
- Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance.Diabetes, metabolic syndrome and obesity : targets and therapy · 2022Review
- An overview of chiral separations of pharmaceutically active substances by HPLC (2018-2020).Monatshefte fur chemie · 2021Review
- The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development.International journal of molecular sciences · 2018Review
- Linagliptin-associated blistering and ulceration.BMJ case reports · 2017Article
- Uncertainties around incretin-based therapies: A literature review.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2017Review
- Dipeptidyl-peptidase-4 inhibitor, alogliptin, attenuates arterial inflammation and neointimal formation after injury in low-density lipoprotein (LDL) receptor-deficient mice.Journal of the American Heart Association · 2015Article
- Alogliptin (nesina) for adults with type-2 diabetes.P & T : a peer-reviewed journal for formulary management · 2014Article
- Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus.Diabetes, metabolic syndrome and obesity : targets and therapy · 2014Review
- Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studies.BMC endocrine disorders · 2013Article
- Improved function and proliferation of adult human beta cells engrafted in diabetic immunodeficient NOD-scid IL2rγ(null) mice treated with alogliptin.Diabetes, metabolic syndrome and obesity : targets and therapy · 2013Article
- Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin.Drug design, development and therapy · 2013Review
- Potent antiatherosclerotic effects of alogliptin in addition to its potent antidiabetic effects.Diabetes, metabolic syndrome and obesity : targets and therapy · 2012Article
- Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore.Journal of medicinal chemistry · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlogliptin is an oral antihyperglycemic agent that is a selective inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4). Inhibition of DPP-4 elevates levels of the incretin hormones glucagon-like peptide (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) by preventing their degradation.
objectiveTo review the evolution of alogliptin and its pharmacokinetics, pharmacodynamics, clinical efficacy and adverse effects. In addition, we compared alogliptin to other DPP-4 inhibitors.
methodsA comprehensive literature search was performed using the term 'alogliptin'. Original research articles and review articles as well as scientific abstracts were included.
resultsAlogliptin raises postprandial levels of GLP-1. It has excellent bioavailability exhibiting a median T(max) ranging from 1 to 2 hours and a mean half-life of 12.4 to 21.4 hours across all doses. When given as monotherapy, mean hemoglobin A(1c) (HbA(1c)) reductions achieved were 0.5% to 0.6%. Combination therapy yielded similar reductions (-0.5% with metformin, -0.6% with glyburide, -0.8% with pioglitazone and -0.6% with insulin). Administration of alogliptin does not promote weight loss but has not resulted in weight gain. The agent is relatively well tolerated with few adverse effects, the major finding being a marginally higher rate of skin events, primarily pruritus.
conclusionsAlogliptin causes significant reductions in HbA(1c) when used alone or in combination with other oral agents in patients with type 2 diabetes similar to other DPP-4 inhibitors in current clinical use. The side effect profile also does not differ from that of other DPP-4 inhibitors. However, long-term studies are necessary before the place of alogliptin in the management of type 2 diabetes can be established.
Indexed as
Identifiers
21437125PMC3048010What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.